1. A filamentous bacteriophage for use in the treatment of Parkinson's disease or a predisposition to Parkinson's disease, where the filamentous bacteriophage does not carry (i) an internalization signal to mammalian cells； (ii) an α-synuclein antigen or anti-α-synuclein antibody； or (iii) β-amyloid antigen or anti-β-amyloid antibody. 2. The filamentous bacteriophage according to claim 1, wherein the bacteriophage is a wild-type (WT) phage. The filamentous bacteriophage or use according to claim 2, wherein the bacteriophage is a UV-irradiated phage. 4. The filamentous bacteriophage according to claim 1 or 2, selected from the bacteriophage M13, f1 and fd. 5. The filamentous bacteriophage according to claim 4, wherein the filamentous bacteriophage is M13.6. A pharmaceutical composition comprising a) a first filiform bacteriophage carrying an antibody specific for a pro-inflammatory cytokine； b) a second filamentous bacteriophage where the second bacteriophage does not carry (i) an internalization signal to mammalian cells； (ii) an α-synuclein antigen or anti-α-synuclein antibody； β-amyloid antigen or anti-β-amyloid antibody； or (iv) an antibody specific for a pro-inflammatory cytokine； and c) a pharmaceutically acceptable carrier. 7. The composition according to claim 6, prepared for intranasal administration. The composition of claim 6, wherein the first bacteriophage does not carry an internalization signal to mammalian cells. The composition of claim 6, wherein the second bacteriophage is a wild-type (WT) phage. The composition of claim 9, wherein the second bacteriophage is a UV-irradiated bacteriophage. The composition of claim 6, wherein the first filamentous bacteriophage further carries a portion of protein A or protein G that binds antibodies, and where the antibody that binds to a pro-inflammatory cytokine is associated with a portion of protein A or protein G that binds antibodies.1. Нитевидный бактериофаг для применения в лечении болезни паркинсона или пр
